Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

Results

Title:	Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
Authors:	Nikolić, Vladimir ; Ciuleanu T; Shacham E; Vrbanec D; Plate S; Mrsic Z; Kahan Z; Purkalne G; Brodowicz T; Zielinski C
Issue Date:	2011
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Search Idenfier
Publisher:	American Society of Clinical Oncology, Ilinois, SAD
Type:	Conference Paper
Collation:	vol. 29 br. 15 str. 494-494
DOI:	10.1200/jco.2011.29.4_suppl.494
WoS-ID:	000208847100491
URI:	https://enauka.gov.rs/handle/123456789/291232
Metadata source:	Migracija
M-category:	Mp. category will be shown later

2
OpenCitations

Altmetric

Dimensions

Unpaywall

Google Scholar^TM